Post J, Frishman W. Fenoldopam: a new dopamine agonist for the treatment of hypertensive urgencies and emergencies. J Clin Pharmacol. 1998;38:2-13.

Abdelwahab W, Frishiman W, Landau A. Management of hypertensive urgencies and emergencies. J Clin Pharmacol. 1995;35:747-762.

Cooper Z, Mihm F. Blood pressure control with fenoldopam during excision of a Pheochromocytoma. Anesthesiology. 1999;91:558-560.

Holcslaw T, Beck T. Clinical experience with intravenous fenoldopam. Am J Hypertens. 1990;3:120S-125S.

Lokhandwala M, Steenberg M. J Auton Pharmacol. 1984;4:273-277.

Ohlstein E, Zabko-Potapovich B, Berkowitz B. Studies on vascular dopamine receptors with the dopamine receptor agonist: SK&F 82526. J Pharmacol Exp Ther. 1984;229:433-439.

Kohli J, Glock D, Goldberg L. Relative DA1-dopamine receptor agonist and a-adrenoceptor antagonist activity of fenoldopam in the anesthetized dog. J Cardiovasc Pharmacol. 1988;11:123-126.

Singer I, Epstein M. Potencial of dopamine A-1 agonists in the management of acute renal failure. Am J Kidney Dis. 1998;31:743-755.

Lokhandwala M, Watkins H, Sabouni M. Pharmacological analysis of the actions of SKF 82526 on cardiovascular dopamine receptors. J Pharmacol Exp Ther. 1985;234:337-344.

Dupont A, Lefebvre R, Vanderniepen P. Influence of the dopamine receptor agonists fenoldopam and quinpirole in the rat superior mesenteric vascular bed. Br J Pharmacol. 1987;91:493-501.

Zhao R, Fennel W, Abel F. Effects of dopamine D1 and dopamine D2 receptor agonists on coronary and peripheral hemodynamics. Eur J Pharmacol. 1990;190:193-202.

Zhao R, Wang P, Zhang W. Analysis of the effects of dopamine-1 and dopamine-2 receptor agonists on coronary flow: Methods Find Exp. Clin Pharmacol. 1992;14:5-11.

Lappe R, Todt J, Wendt R. Effects of fenoldopam on regional vascular resistance in conscious spontaneously hypertensive rats. J Pharmacol Exp Ther. 1986;236:187-191.

Aronson S, Goldberg L, Glock D. Effects of fenoldopam on renal blood flow and systemic hemodynamics during isoflurane anesthesia. J Cardiothorac Vasc Anesth. 1991;5:29-32.

Dlewati A, Lokhandwala F. Dose-response analysis of the effect of fenoldopam, a dopamine-1 receptor agonist, on renal function. Drug Dev Res. 1991;22:59-68.

Allison N, Dubb J, Ziemniak J. The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin Pharmacol Ther. 1987;41:282-288.

Taylor A, Luther R, Fellmann J. Pharmacodynamics of prolonged infusions of fenoldopam in patients with moderately severe hypertension. J Clin Pharmacol. 1995;35:932.

Elliott W, Weber R, Nelson K. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation. 1990;81:970-977.

White W, Radford M, Gonzales F. Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam. J Am Coll Cardiol. 1988;11:1118-1123.

Bodmann K, Tröster S, Clemens R. Hemodynamic profile of intravenous fenoldopam in patient with hypertensive crisis. Clin Investig. 1993;72:60-64.

Shusterman N, Elliott W, White W. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med. 1993;95:161-168.

Smit A. Dopamine in chronic renal failure. Am J Hypertens. 1990;3:75-77.

Girbes A, Smit A, Meijer S. Renal and endocrine effects of fenoldopam and metoclopramide in normal man. Nephron. 1990;56:179-185.

Ruilope L, Robles R, Miranda B. Renal effects of fenoldopam in refractory hypertension. J Hypertens. 1988;6:665-669.

White W, Halley S. Comparative renal effects of intravenous fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension. Arch Intern Med. 1989;149:870-874.

MacDonald T, Jeffrey R, Freestone S. A single dose study of the effects of fenoldopam and enalapril in mild hypertension. Eur J Clin Pharmacol. 1991;40:231-236.

Poinsot A, Romand J, Favre H. Fenoldopam improves renal hemodynamics impaired by positive end-expiratory pressure. Anesthesiology. 1993;79:680-684.

Blanchett D, Green J, Nara A. The effect of food on the pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure. Clin Pharmacol Ther. 1991;49:449-456.

Clancy A, Locke-Haydon J, Cregeen R. Effects of concomitant food intake on absortion kinetics of fenoldopam (SK&F 82526) in healthy volunteers. Eur J Clin Pharmacol. 1987;32:103-106.

Ziemniak J, Allison N, Boppan V. The effect of acetaminophen on the disposition of fenoldopam: competition for sulfaction. Clin Pharmacol Ther. 1987;41:275-281.

Weber R, McCoy C, Ziemniak J. Pharmacokinetics and pharmacodynamic properties of intravenous fenoldopam. Br J Clin Pharmacol. 1988;25:17-21.

Brogden R, Markhan A. Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potencial in the management of hypertensive urgencies and emergencies. Drugs. 1997;54:634-650.

Bednarczyk E, White W, Munger M. Comparative acute blood pressure reduction from intravenous fenoldopam mesylate versus sodium nitroprusside in severe systemic hypertension. Am J Cardiol. 1989;63:993-996.

Pilmer B, Green J, Panacek E. Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic hypertension. J Clin Pharmacol. 1993;33:549-553.

Reisin E, Huth M, Nguyen B. Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension. Hypertension. 1990;15:59-62.

Elliott W, Karnezis T, Silverman R. Intraocular pressures increases with fenoldopam, but not nitroprusside, in hypertensive humans. Clin Pharmacol Ther. 1991;49:285-293.

Panacek E, Bednarczyk E, Dunbar L. Randomized, prospective trial of fenoldopam versus sodium nitroprusside in the treatment of acute severe hypertension. Acad Emerg Med. 1995;2:959-965.

Strocchi E, Tartagni F, Malini P. Interaction study of fenoldopam-digoxin in congestive heart failure. Eur J Clin Pharmacol. 1989;37:395-397.

Shao Z, Pania S, Yaacoub A. Attenuation of the vascular effects of DA-1 receptor agonist, fenoldopam, by allopurinol. Am J Hypertens. 1992;5(^s2):121A.

Hughes J, Ragsdale N, Felder R. Diuresis and natriuresis during continuous dopamine-1 receptor stimulation. Hypertension. 1988;11(^s2):I69-I74.

Murphy M, McCoy C, Weber R. Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of dopamine-1 agonist fenoldopam. Circulation. 1987;76:1312-1318.

Goldberg M, Cantillo J, Nemirof M. Fenoldopam infusion for the treatment of postoperative hypertension. J Clin Anesth. 1993;5:386-391.

Hill A, Feneck R, Walesby R. Comparison of fenoldopam and nitroprusside in the control of hypertension following coronary artery surgery. J Cardiothorac Vasc Anesth. 1993;7:279-284.

Karnesiz T, Murphy M, Weber R. Effect of seletive dopamine-1 receptor activation on intraocular pressure in man. Exp Eye Res. 1988;47:689-697.

Oparil S, Chair , Aronson S. Fenoldopam: a new parenteral antihypertensive: Consensus roundtable on the management of perioperative hypertension and hypertensive crises. Am J Hypertens. 1999;12:653-664.

Frishman W, Hotchkiss H. Selective and nonselective dopamine receptor agonists: an innovative approach to cardiovascular disease treatment. Am Heart J. 1996;132:861-870.

Singh N, Goyal R. New classes of antihypertensive drugs: therapeutic potencials. Clin Exp Hypertens. 1999;21:137-143.

Yoshimura M, Ikegaki I, M Nishimura. Role of dopaminergic mechanisms in the kidney for the pathogenesis of hypertension. Auton Pharmacol. 1990;10(^s1):S67-S72.